These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27268204)

  • 1. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
    Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
    Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
    Baron BW; Anastasi J; Thirman MJ; Furukawa Y; Fears S; Kim DC; Simone F; Birkenbach M; Montag A; Sadhu A; Zeleznik-Le N; McKeithan TW
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2860-5. PubMed ID: 11854457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
    Bal E; Kumar R; Hadigol M; Holmes AB; Hilton LK; Loh JW; Dreval K; Wong JCH; Vlasevska S; Corinaldesi C; Soni RK; Basso K; Morin RD; Khiabanian H; Pasqualucci L; Dalla-Favera R
    Nature; 2022 Jul; 607(7920):808-815. PubMed ID: 35794478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
    Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
    Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.
    Batlle-López A; Cortiguera MG; Rosa-Garrido M; Blanco R; del Cerro E; Torrano V; Wagner SD; Delgado MD
    Oncogene; 2015 Jan; 34(2):246-56. PubMed ID: 24362533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 18. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
    Sandhu SK; Volinia S; Costinean S; Galasso M; Neinast R; Santhanam R; Parthun MR; Perrotti D; Marcucci G; Garzon R; Croce CM
    Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20047-52. PubMed ID: 23169640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers.
    Mascle X; Albagli O; Lemercier C
    Biochem Biophys Res Commun; 2003 Jan; 300(2):391-6. PubMed ID: 12504096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
    Parekh S; Privé G; Melnick A
    Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.